AdaptHealth Corp Dossier - Source-backed chat

AdaptHealth Corp

AHCONASDAQ

SectorHealth Care

IndustryMedical Devices

Beta (adjusted)1.31

Intrinsic Value $10.73median of 3 methodsbased on filings through 30 Jun 2026

Market Price $5.64Price as of 30 Sep 2026

Significantly undervaluedIntrinsic value is 90% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+90%)

Data confidence Sign in to view data confidence

Market Cap $752.4M

Enterprise Value $2.6B

Shares Outstanding 136.2M diluted

Moat Rating None

Next Earnings Date6 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

AdaptHealth Corp. is transitioning from a highly leveraged, acquisition-heavy roll-up model to an organic, technology-driven growth platform. The company's successful onboarding of a massive new capitated contract covering over 10 million members has significantly boosted organic revenue growth (9.1% in Q1 2026). While near-term profitability has been temporarily compressed by elevated transition labor costs and capital expenditures, the underlying earnings power remains robust. Furthermore, the successful $1.1 billion refinancing in April 2026 has extended debt maturities to 2031, lowered the weighted average cost of debt, and provided a clear path to redeem high-interest senior notes in August 2026. Trading at an attractive forward valuation, AdaptHealth represents a compelling value opportunity in the expanding home healthcare and chronic disease management markets.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$9.14

High · most bullish analyst$10.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$7.0015%

Labor inefficiencies and elevated onboarding costs under the capitated contract persist throughout 2026, leading to a downward revision of Adjusted EBITDA guidance. Renewed supply chain disruptions or competitive pricing pressures in the diabetes pharmacy channel further compress margins, keeping free cash flow near the lower bound of guidance.

Base CaseCentral scenario

$9.1460%

Matches the consensus mean

AdaptHealth successfully delivers on its revised FY 2026 guidance, achieving net revenue of $3.45 billion to $3.52 billion and Adjusted EBITDA of $680 million to $730 million. Transition labor costs moderate as expected in the second half of 2026, and free cash flow recovers to the guided range of $175 million to $225 million. The 6.125% Senior Notes are fully redeemed in August 2026, reducing interest expense.

Bull CaseUpside scenario

$10.0025%

Rapid normalization of capitated contract labor costs drives Adjusted EBITDA margins toward the high end of the 19% target. Accelerated adoption of the myApp portal and AI-enabled touchless scheduling reduces SG&A expenses. Strong organic growth in high-margin sleep and diabetes segments exceeds expectations, pushing full-year free cash flow above the $225 million guidance ceiling.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong organic revenue growth (9.1% in Q1 2026) driven by the largest patient transition in home medical equipment history.
Successful $1.1 billion credit facility refinancing in April 2026, extending maturities to 2031 and lowering the cost of debt.
Exclusive long-term capitated contracts covering over 10 million members, creating a highly defensive, low-acquisition-cost referral channel.
Rapidly expanding digital engagement, with myApp portal users growing 26% quarter-over-over to 412,000 in Q1 2026.

Key Investment Risks

Near-term margin compression from elevated labor and implementation costs associated with onboarding the new capitated contract.
High debt leverage (total long-term debt of approximately $1.82 billion as of March 31, 2026) restricting strategic flexibility.
Reimbursement risks from government (Medicare/Medicaid) and commercial payors, including potential unilateral rate cuts.

Thesis Invalidation Triggers

Failure of Adjusted EBITDA margins to normalize toward the guided ~19% level in Q2 2026 and beyond.
Inability to redeem the 6.125% Senior Notes due 2028 in August 2026, indicating liquidity constraints.
A material downward revision of full-year 2026 Adjusted EBITDA or free cash flow guidance.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.